Package Leaflet: Information for the User
Balzak Plus 20 mg/5 mg/12.5 mg film-coated tablets
Olmesartan medoxomil / Amlodipine / Hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Balzak Plus contains three active substances called olmesartan medoxomil, amlodipine (as amlodipine besylate) and hydrochlorothiazide. These three substances help to control high blood pressure.
The action of these substances contributes to lowering your blood pressure.
Balzak Plus is used to treat high blood pressure:
Do not take Balzak Plus
If you think you may be allergic, inform your doctor before taking Balzak Plus.
Do not take Balzak Plus if any of these apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Balzak Plus.
Tell your doctorif you are taking any of the following medicines used to treat high blood pressure (hypertension):
Your doctor may need to monitor your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Balzak Plus”.
Tell your doctorif you have any of the following health problems:
Consult your doctor if you experience any of the following symptoms:
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking Balzak Plus. Your doctor will decide whether to continue treatment. Do not stop taking Balzak Plus on your own.
As with any other blood pressure-lowering medicine, excessive lowering of blood pressure in patients with impaired blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
Balzak Plus may cause an increase in blood lipid and uric acid levels (which can cause gout - painful swelling of the joints). Your doctor will likely want to perform a blood test from time to time to monitor these possible changes.
A change in blood levels of certain chemicals called electrolytes may occur. Your doctor will likely want to perform a blood test from time to time to monitor this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling of weakness, slowness, tiredness, drowsiness or restlessness, nausea, vomiting, decreased need to urinate, rapid heartbeat. Tell your doctor if you notice any of these symptoms.
If you are going to have parathyroid function tests, you must stop taking Balzak Plus before these tests are performed.
Athletes are informed that this medicine contains a component that may result in a positive doping test.
You must inform your doctor if you are pregnant (or think you might be). It is not recommended to use Balzak Plus at the start of pregnancy, and it must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage (see section “Pregnancy and breast-feeding”).
Children and adolescents (under 18 years)
The use of Balzak Plus is not recommended in children and adolescents under 18 years.
Using Balzak Plus with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines:
Your doctor may need to adjust your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Balzak Plus” and “Warnings and precautions”).
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines for:
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicine.
Taking Balzak Plus with food and drinks
Balzak Plus can be taken with or without food.
People taking Balzak Plus should not consume grapefruit or grapefruit juice. This is because grapefruit and grapefruit juice can lead to an increase in the levels of the active ingredient amlodipine in the blood, which can cause an unpredictable increase in the blood pressure-lowering effect of Balzak Plus.
Be careful when drinking alcohol while taking Balzak Plus, as some people feel faint or dizzy. If this happens, do not drink any alcohol.
Elderly patients
If you are over 65 years old, your doctor will regularly monitor your blood pressure whenever your dose is increased, to ensure that your blood pressure does not drop too much.
Pregnancy and breast-feeding
Pregnancy
You must inform your doctor if you are pregnant (or think you might be). Your doctor will advise you to stop taking Balzak Plus before you become pregnant or as soon as you know you are pregnant, and will advise you to take a different medicine instead of Balzak Plus. It is not recommended to use Balzak Plus during pregnancy, and it must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage.
If you become pregnant while taking Balzak Plus, inform and consult your doctor immediately.
Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. It has been shown that amlodipine and hydrochlorothiazide pass into breast milk in small amounts. It is not recommended to use Balzak Plus in breast-feeding mothers, and your doctor may choose a different treatment if you wish to breast-feed.
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
You may feel drowsy, sick, or dizzy, or have a headache while being treated for high blood pressure. If this happens, do not drive or use machines until the symptoms have disappeared. Consult your doctor.
This medicine contains less than 1 mmol of sodium (23 mg) per film-coated tablet; this is essentially “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
If you take more Balzak Plus than you should
If you take more tablets than you should, you will probably suffer from a drop in blood pressure, accompanied by symptoms such as dizziness, and fast or slow heartbeat.
If you take more tablets than you should or if a child accidentally ingests some tablets, contact your doctor or go to the nearest emergency center immediately and bring the medication package or this leaflet with you.
Excess fluid may accumulate in the lungs (pulmonary edema) causing difficulty breathing that can develop up to 24-48 hours after ingestion.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20.
If you forget to take Balzak Plus
If you forget to take a dose, take the usual dose the next day. Do not take a double dose to make up for the missed doses.
If you interrupt treatment with Balzak Plus
It is important to continue taking Balzak Plus, unless your doctor tells you to interrupt treatment.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not all people suffer from them. If they occur, they are often mild and do not require interrupting treatment.
The following side effects may be serious, although they affect only a small group of people:
During treatment with Balzak Plus, allergic reactions with inflammation of the face, mouth, and/or larynx (vocal cords), along with itching and skin rash, may occur. If this happens to you, stop taking Balzak Plus and consult your doctor immediately.
Balzak Plus may cause a pronounced drop in blood pressure in susceptible patients. This can cause fainting or severe dizziness. If this happens to you, stop taking Balzak Plus, consult your doctor immediately, and remain lying down in a horizontal position.
Frequency not known: If you experience yellowing of the whites of the eyes, dark urine, itching of the skin, even if you started treatment with Balzak Plus a long time ago, contact your doctor immediatelywho will evaluate your symptoms and decide how to continue treatment for blood pressure.
Balzak Plus is a combination of three active substances. The following information describes the side effects reported so far with the Balzak Plus combination (in addition to those already mentioned) and the side effects known for each of the active substances separately, or when two of the substances are taken together.
To give you an idea of the number of patients who may have side effects, they have been classified as frequent, uncommon, rare, and very rare.
These are other known side effects with Balzak Plus:
If these effects occur, they are often mild and it is not necessary to interrupt treatment.
Frequent
(may affect up to 1 in 10 people)
Upper respiratory tract infection, sore throat and nose, urinary tract infection, dizziness, headache, perception of heartbeats, low blood pressure, nausea, diarrhea, constipation, cramps, joint swelling, urge to urinate, weakness, ankle swelling, fatigue, abnormal laboratory test values.
Uncommon
(may affect up to 1 in 100 people)
Dizziness when standing up, vertigo, fast heartbeat, feeling of fainting, flushing and feeling of heat in the face, cough, dry mouth, muscle weakness, inability to have or maintain an erection.
These are the side effects known for each of the active substances separately or when two of the substances are taken together:
They may be side effects due to Balzak Plus, even if they have not been observed so far with Balzak Plus.
Very common
(may affect more than 1 in 10 people)
Edema (fluid retention).
Frequent
(may affect up to 1 in 10 people)
Bronchitis, stomach and intestine infection, vomiting, increased blood sugar, sugar in urine, confusion, drowsiness, visual disturbances (including double vision and blurred vision), nasal congestion, sore throat, difficulty breathing, cough, abdominal pain, heartburn, stomach discomfort, flatulence, joint or bone pain, back pain, bone pain, blood in urine, flu-like symptoms, chest pain, pain.
Uncommon
(may affect up to 1 in 100 people)
Reduction in the number of a type of blood cells called platelets, which can cause easy bruising or prolonged bleeding, anaphylactic reactions, abnormal loss of appetite (anorexia), sleep problems, irritability, mood changes including anxiety, feeling of depression, chills, sleep disorders, alteration of the sense of taste, loss of consciousness, decreased sense of touch, tingling sensation, worsening of myopia, ringing in the ears (tinnitus), angina (pain or unpleasant sensation in the chest, known as angina pectoris), irregular heartbeats, rash, hair loss, allergic skin inflammation, skin redness, purple spots or patches on the skin due to small hemorrhages (purpura), skin discoloration, red itchy patches (urticaria), increased sweating, itching, skin rash, skin reactions to light, such as sunburn or skin rash, muscle pain, urination problems, feeling of needing to urinate at night, breast enlargement in men, decreased sexual desire, facial swelling, feeling of discomfort, weight gain or loss, exhaustion.
Rare
(may affect up to 1 in 1,000 people)
Inflammation and pain of the salivary glands, decrease in the number of white blood cells in the blood, which could increase the risk of infections, decrease in the number of red blood cells (anemia), bone marrow damage, restlessness, feeling of loss of interest (apathy), seizures (convulsions), yellowish vision, dry eyes, blood clots (thrombosis, embolism), fluid accumulation in the lungs, pneumonia, inflammation of blood vessels and small blood vessels in the skin, pancreatitis, yellowing of the skin and eyes, acute inflammation of the gallbladder, symptoms of lupus erythematosus such as skin rash, joint pain, and cold hands and fingers, severe skin reactions including intense skin rash, urticaria, skin redness of the body, severe itching, blisters, peeling, and skin inflammation, inflammation of the mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis), sometimes very severe, movement impairment, acute kidney failure, non-infectious kidney inflammation, decreased kidney function, fever; intestinal angioedema: swelling in the intestine that occurs with symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Very rare
(may affect up to 1 in 10,000 people)
High muscle tension, numbness of hands or feet, heart attack, stomach inflammation, gum thickening, intestinal obstruction, liver inflammation, acute breathing difficulty (the signs include severe breathing difficulty, fever, weakness, and confusion).
Side effects of unknown frequency
(cannot be estimated from the available data)
Decreased vision or eye pain (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).
Tremors, rigid posture, mask-like face, slow movements, and unsteady gait.
Skin and lip cancer (non-melanoma skin cancer).
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date that appears on the package and blister pack (after "CAD"). The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be thrown down the drain or into the trash. Deposit the packages and medications you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packages and medications you no longer need. This will help protect the environment.
Composition of Balzak Plus
The active ingredients are olmesartan medoxomil, amlodipine (as amlodipine besylate), and hydrochlorothiazide.
Each film-coated tablet contains 20 mg of olmesartan medoxomil, 5 mg of amlodipine (as amlodipine besylate), and 12.5 mg of hydrochlorothiazide.
The other components are:
Core of the tablet: Pregelatinized cornstarch, microcrystalline cellulose, anhydrous colloidal silica, sodium croscarmellose, and magnesium stearate.
Tablet coating: Poly(vinyl alcohol), macrogol 3350, talc, titanium dioxide (E-171), iron oxide (III) yellow (E-172), iron oxide (III) red (E-172), and iron oxide (II, III) black (E-172).
Appearance of the product and package contents
Balzak Plus 20 mg/5 mg/12.5 mg film-coated tablets are light orange, round tablets of 8 mm, with the inscription "C51" on one side.
Balzak Plus film-coated tablets are presented
Not all packages are marketed.
Marketing authorization holder
Menarini International Operations Luxembourg, S.A.
1, Avenue de la Gare
L-1611 Luxembourg
Local representative:
Laboratorios Menarini, S.A.
Alfons XII, 587 – E 08918 Badalona (Barcelona)
Manufacturer
DAIICHI SANKYO EUROPE GmbH
Luitpoldstrasse 1
85276 Pfaffenhofen
Germany
or
BERLIN-CHEMIE AG
Glienicker Weg 125
12489 Berlin
Germany
or
MENARINI – VON HEYDEN GmbH
Leipziger Strasse 7-13
01097 Dresden
Germany
This medication is authorized in the member states of the European Economic Area with the following names:
Austria: Amelior plus HCT 20 mg/5 mg/12.5 mg
Belgium: Forzaten/HCT 20 mg/5 mg/12.5 mg
Bulgaria: Tespadan HCT 20 mg/5 mg/12.5 mg
Cyprus: Orizal plus 20 mg/5 mg/12.5 mg
Czech Republic: Sintonyn Combi 20 mg/5 mg/12.5 mg
Estonia: Sanoral HCT 20 mg/5 mg/12.5 mg
Germany: Vocado HCT 20 mg/5 mg/12.5 mg
Greece: Orizal plus 20 mg/5 mg/12.5 mg
Hungary: Duactan HCT 20 mg/5 mg/12.5 mg
Ireland: Konverge Plus 20 mg/5 mg/12.5 mg
Latvia: Sanoral HCT 20 mg/5 mg/12.5 mg
Lithuania: Sanoral HCT 20 mg/5 mg/12.5 mg
Luxembourg: Forzaten HCT 20 mg/5 mg/12.5 mg
Netherlands: Belfor HCT 20 mg/5 mg/12.5 mg
Malta: Konverge Plus 20 mg/5 mg/12.5 mg
Poland: Elestar HCT 20 mg/5 mg/12.5 mg
Portugal: Zolnor HCT 20 mg/5 mg/12.5 mg
Romania: Inovum HCT 20 mg/5 mg/12.5 mg
Slovakia: Folgan HCT 20 mg/5 mg/12.5 mg
Slovenia: Olectan HCT 20 mg/5 mg/12.5 mg
Spain: Balzak Plus 20 mg/5 mg/12.5 mg
Date of the last revision of this leaflet:January 2025
Other sources of information
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of BALZAK PLUS 20 mg/5 mg/12.5 mg FILM-COATED TABLETS in October, 2025 is around 15.52 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.